Education
About Us
Working with TipRanks
Follow Us
Emergent Biosolutions (EBS)
NYSE:EBS
Earnings Data
Report Date
Mar 10, 2026TBA (Confirmed)
Period Ending
2025 (Q4)Consensus EPS Forecast
0.38Last Year’s EPS
0.05Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
Emergent BioSolutions reported a strong quarter, exceeding revenue and profitability expectations, and increased financial guidance for the year. The company's liquidity remains robust, with significant growth in the naloxone business and international revenue. Despite a decline in year-to-date revenues due to previous divestitures and variability in Canadian sales, the overall outlook remains positive.Company Guidance
Exceeded Revenue and Profitability Expectations
Third quarter revenues of $231 million were $21 million above the high end of Q3 guidance. Year-to-date, $194 million of adjusted EBITDA was generated, reaching the high end of the full-year guidance.
Increased Financial Guidance
Emergent raised its total revenue guidance to $775 million to $835 million and adjusted EBITDA guidance to $195 million to $210 million, reflecting a $15 million increase at the midpoint.
Strong Liquidity and Cash Position
Access to $346 million in financial capacity, including $246 million of balance sheet cash and an undrawn revolver. Net leverage improved to approximately 2x net debt to adjusted EBITDA.
Naloxone Business Growth
NARCAN unit volume grew by 13% quarter-over-quarter, with revenue growth of 9%. Continued market leadership in the naloxone category.
International Revenue Growth
International customers represent 34% of MCM sales year-to-date, up from the mid- to high teens in previous years.
EBS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
EBS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Oct 29, 2025 | $9.40 | $12.84 | +36.60% |
Aug 06, 2025 | $6.03 | $8.24 | +36.65% |
May 07, 2025 | $4.74 | $6.36 | +34.18% |
Mar 03, 2025 | $6.83 | $6.39 | -6.44% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Emergent Biosolutions (EBS) report earnings?
Emergent Biosolutions (EBS) is schdueled to report earning on Mar 10, 2026, TBA (Confirmed).
What is Emergent Biosolutions (EBS) earnings time?
Emergent Biosolutions (EBS) earnings time is at Mar 10, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is EBS EPS forecast?
EBS EPS forecast for the fiscal quarter 2025 (Q4) is 0.38.